Q-omics provides the consensus-scored CKS1BP7 profile across patient tissues and cancer cell-line models. CKS1BP7 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CKS1BP7 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, CKS1BP7 RNA expression shows 18,525 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, BLCA, and GBM as cancer lineages where CKS1BP7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CKS1BP7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CKS1BP7 survival associations across molecular data types. CKS1BP7 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CKS1BP7 RNA expression–survival associations across cancer types. High CKS1BP7 expression shows unfavorable associations in UVM, ACC, KICH and PAAD, but favorable associations in KIRC and BLCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CKS1BP7 RNA expression.
This table summarizes CKS1BP7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for CKS1BP7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CKS1BP7 shows higher tumor expression in BLCA, HNSC, COAD, KIRC, LUAD and LUSC. The BLCA box plot shows higher CKS1BP7 RNA expression in tumor versus normal tissue (log2 FC = +0.607, t-test p < 0.001).
This table shows molecular features associated with CKS1BP7 in patient tissues and cancer cell lines. In patient samples, CKS1BP7 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
